You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 12 Current »

Is it appropriate to use NHOID in this example where you are testing anti-RSV IgG antibody in the patient? In this assessment, the microbe is not the subject of the observation, this is measuring the host/subject immune response.

In reference to the published examples where NHOID is used, observations are made and tests are run on the microbe itself - the results tell you something about and relevant to the microbe:

  • is it susceptible to an antibiotics? (MS)
  • does it have some mutations or sequence changes in its genome? (GF)
  • can the subject antibody stop it from infecting cells? (IS)
  • for all of the above, you are running tests that have a direct impact on the microbe, or the observations/assessments tell you something about the microbe, but not necessarily about the host/subject.

In the below example, this is a use-case where the subject's humoral immune responses are measured by the quantification of anti-RSV IgG antibody toward vaccine-delivered RSV antigens (proteins B and Z), the observations (results) are about the study subject's protective antiviral antibody levels which indicates how he responds to the vaccine stimulation. It doesn't tell you anything about the bugs. Normally and traditionally, the model would look like example 1. However, in reality, what needs to be collected and modeled is Example 2.

Having NHOID in example 2 helps to identify the specific strains from which the vaccine is derived, but this is beyond the scope of how NHOID is defined and used.

Question: Can we expand the scope of NHOID in this case? Why was the variable scope limited to "observations about the non-host microbe" in the first place, what were/are the concerns?


Example 1: Without NHOID, in the example below, all you know is that two types of vaccine-delivered RSV antigens had successfully stimulated antibody responses in this subject. Where do you map the info that the antibody targets (in ISBDAGNT), HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN B, and HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN Z, are actually from two different strains of RSV virus?

  • HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN B is from the strain Human respiratory syncytial virus MinA    
  • HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN Z is from the strain Human respiratory syncytial virus (strain RSP112/Sweden/02-03)   

$titleHtml

is.xpt

Row

STUDYID

DOMAIN

USUBJID

ISSEQ

ISGRPID

ISTESTCD

ISTEST

ISBDAGNT

ISTSTOPO

ISCAT

ISSCAT

ISORRES

ISSTRESC

ISSTRESN

ISSTRESU

ISSPEC

ISMETHOD

VISITNUM

VISIT

ISDTC

1

RSV1230

IS

RSV1230-011

11

MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN B

SCREEN

STUDY VACCINE-RELATED IMMUNOGENICITYHUMORAL IMMUNITY

POSITIVE

POSITIVE



SERUM

ELISA

1

BASELINE

2017-05-27

2

RSV1230

IS

RSV1230-011

21MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN B

QUANTIFY

STUDY VACCINE-RELATED IMMUNOGENICITY

HUMORAL IMMUNITY

1:25

25

25titer

SERUM

ELISA

1

BASELINE

2017-05-27

3

RSV1230

IS

RSV1230-011

12

MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN Z

SCREEN

STUDY VACCINE-RELATED IMMUNOGENICITYHUMORAL IMMUNITYPOSITIVEPOSITIVE

SERUM

ELISA

1

BASELINE

2017-05-27

4

RSV1230

IS

RSV1230-011

22

MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN Z

QUANTIFY

STUDY VACCINE-RELATED IMMUNOGENICITYHUMORAL IMMUNITY1:120120120titer

SERUM

ELISA

1

BASELINE

2017-05-27

5

RSV1230

IS

RSV1230-011

1
MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN B

QUANTIFY

STUDY VACCINE-RELATED IMMUNOGENICITY

HUMORAL IMMUNITY

1:90

90

90

titer

SERUM

ELISA

2

VISIT 1

2017-07-27

6RSC1230IS

RSV1230-011

2
MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN B

QUANTIFY

STUDY VACCINE-RELATED IMMUNOGENICITY

HUMORAL IMMUNITY1:220220220titer

SERUM

ELISA

3VISIT 22017-08-27
7

RSV1230

IS

RSV1230-011

1
MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN Z

QUANTIFY

STUDY VACCINE-RELATED IMMUNOGENICITY

HUMORAL IMMUNITY

1:140

140

140titer

SERUM

ELISA

2

VISIT 1

2017-07-27

8RSC1230IS

RSV1230-011

2
MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN Z

QUANTIFY

STUDY VACCINE-RELATED IMMUNOGENICITY

HUMORAL IMMUNITY1:400400400titer

SERUM

ELISA

3VISIT 22017-08-27
$warningHtml

Example 2: With NHOID, but this is stretching the scope of this variable.

$titleHtml

is.xpt

Row

STUDYID

DOMAIN

USUBJID

NHOIDISSEQ

ISGRPID

ISTESTCD

ISTEST

ISBDAGNT

ISTSTOPO

ISCAT

ISSCAT

ISORRES

ISSTRESC

ISSTRESN

ISSTRESU

ISSPEC

ISMETHOD

VISITNUM

VISIT

ISDTC

1

RSV1230

IS

RSV1230-011

Human respiratory syncytial virus MinA   

11

MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN B

SCREEN

STUDY VACCINE-RELATED IMMUNOGENICITYHUMORAL IMMUNITY

POSITIVE

POSITIVE



SERUM

ELISA

1

BASELINE

2017-05-27

2

RSV1230

IS

RSV1230-011

Human respiratory syncytial virus MinA   21MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN B

QUANTIFY

STUDY VACCINE-RELATED IMMUNOGENICITY

HUMORAL IMMUNITY

1:25

25

25titer

SERUM

ELISA

1

BASELINE

2017-05-27

3

RSV1230

IS

RSV1230-011

Human respiratory syncytial virus (strain RSP112/Sweden/02-03)   

12

MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN Z

SCREEN

STUDY VACCINE-RELATED IMMUNOGENICITYHUMORAL IMMUNITYPOSITIVEPOSITIVE

SERUM

ELISA

1

BASELINE

2017-05-27

4

RSV1230

IS

RSV1230-011

Human respiratory syncytial virus (strain RSP112/Sweden/02-03)   22

MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN Z

QUANTIFY

STUDY VACCINE-RELATED IMMUNOGENICITYHUMORAL IMMUNITY1:120120120titer

SERUM

ELISA

1

BASELINE

2017-05-27

5

RSV1230

IS

RSV1230-011

Human respiratory syncytial virus MinA   1
MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN B

QUANTIFY

STUDY VACCINE-RELATED IMMUNOGENICITY

HUMORAL IMMUNITY

1:90

90

90

titer

SERUM

ELISA

2

VISIT 1

2017-07-27

6RSC1230IS

RSV1230-011

Human respiratory syncytial virus MinA   2
MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN B

QUANTIFY

STUDY VACCINE-RELATED IMMUNOGENICITY

HUMORAL IMMUNITY1:220220220titer

SERUM

ELISA

3VISIT 22017-08-27
7

RSV1230

IS

RSV1230-011

Human respiratory syncytial virus (strain RSP112/Sweden/02-03)   

1
MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN Z

QUANTIFY

STUDY VACCINE-RELATED IMMUNOGENICITY

HUMORAL IMMUNITY

1:140

140

140titer

SERUM

ELISA

2

VISIT 1

2017-07-27

8RSC1230IS

RSV1230-011

Human respiratory syncytial virus (strain RSP112/Sweden/02-03)   2
MBIGGAB

Microbial-induced IgG Antibody

HUMAN RESPIRATORY SYNCYTIAL VIRUS-PROTEIN Z

QUANTIFY

STUDY VACCINE-RELATED IMMUNOGENICITY

HUMORAL IMMUNITY1:400400400titer

SERUM

ELISA

3VISIT 22017-08-27
$warningHtml


  • No labels